An interventional study of GET Living in Chronic Pain, Neuralgia and Musculoskeletal Pain, sponsored by Boston Children's Hospital. Completed at 1 site in United States. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-03-29.
Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Treatment
The broad aim of the study is to implement and evaluate the efficacy of Graded Exposure Treatment (GET Living) to target elevated pain-related fears in children with chronic pain. Pain-related fear is an important psychological factor associated with poor outcomes in children suffering with chronic pain. To examine the efficacy of GET Living in addressing pain-related fears the investigators propose to use a sequential replicated randomized single-case experimental phase design with multiple measures. The specific aims are to 1) evaluate the effectiveness and acceptability of individually tailored GET Living for children with high pain-related fear and functional disability and 2) define anatomical and resting state connectivity patterns in the brains of children and adolescents with complex chronic pain prior to and after participation in GET Living.
493 studies on the registry are indexed under Musculoskeletal Pain; 114 are open to participants now.
This study's enrollment of 34 is below the median of 69 across 346 interventional studies indexed under Musculoskeletal Pain.
Browse Musculoskeletal Pain studies →Boston Children's Hospital is the lead sponsor of 598 studies on the registry; 151 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 18 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Behavioral: GET Living
GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
Decrease in Fear of Pain
Time frame: Decrease in Fear of Pain from Baseline to end of treatment at 6-weeks, on average
Decrease in Functional Disability
Time frame: Decrease in Functional Disability from Baseline to end of treatment at 6-weeks, on average
Improvement in School Functioning
Time frame: Improvement in School Functioning from baseline to end of treatment at 6-weeks, on average
Decrease in Pain Catastrophizing
Time frame: Decrease in Pain Catastrophizing from baseline to end of treatment at 6-weeks, on average
Decrease in Pain Intensity
Time frame: Decrease in Pain Intensity from baseline to end of treatment at 6-weeks, on average
Increase in Physical Activity
Time frame: Increase in Physical Activity from baseline to end of treatment at 6-weeks, on average
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston Children's Hospital